Endpoints' Drew Armstrong and FTC deputy director Rahul Rao at the Financial Times' US Pharma and Biotech Summit (Sarah Merians Photography for Endpoints News)

May 17, 2024 10:00 AM EDT

Pharma

FDA+

Q&A: FTC’s top healthcare enforcer on pharma M&A, company growth and PBMs

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Q&A: FTC’s top healthcare enforcer on pharma M&A, company growth and PBMs

Drew Armstrong

Executive Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Trump administration reveals 'most favored nation' drug price country targets

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

All of 23andMe's independent board members resign over disagreements with CEO

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

Regeneron plans to buy 23andMe for $256M

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Q&A: FTC’s top health­care en­forcer on phar­ma M&A, com­pa­ny growth and PBMs

Executive Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Q&A: FTC’s top healthcare enforcer on pharma M&A, company growth and PBMs